AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32266327 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender equity focused family planning program
Number of subjects: 0
Study 32266379 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric strength training of the spastic muscles for 6 weeks
Number of subjects: 6
Study 32266602 — intervention group
Group type: COMPARATOR
Intervention: Septic patients
Number of subjects: 48
Study 32266602 — intervention group
Group type: COMPARATOR
Intervention: Non-survivors
Number of subjects: 48
Study 32266602 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 48
Study 32266602 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal arteriolar vessels
Number of subjects: 48
Study 32266800 — intervention group
Group type: COMPARATOR
Intervention: Endometrial aspiration biopsy
Number of subjects: 65
Study 32266800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilatation and curettage (D&C)
Number of subjects: 65
Study 32266800 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin treatment regimens (oral medroxyprogesterone acetate (MPA) 10 mg/day for 14 days per cycle, continuous MPA 10 mg/day, levonorgestrel-releasing intrauterine system (LNG-IUS))
Number of subjects: 65
Study 32267227 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) treatment at a fixed 75% degree of maximal protrusion
Number of subjects: 100
Study 32267227 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) treatment
Number of subjects: 100
Study 32267227 — intervention group
Group type: EXPERIMENTAL
Intervention: Position of the soft palate
Number of subjects: 100
Study 32267227 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowding of the oropharynx
Number of subjects: 100
Study 32267227 — intervention group
Group type: EXPERIMENTAL
Intervention: Posteriorly located soft palate with MAD in situ
Number of subjects: 100
Study 32267227 — intervention group
Group type: EXPERIMENTAL
Intervention: Posteriorly located tongue base with MAD in situ
Number of subjects: 100
Study 32267734 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous freshly isolated primary chondrocytes and bone marrow mononucleated cells (MNCs) seeded into a PolyActive scaffold
Number of subjects: 40
Study 32267734 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous freshly isolated primary chondrocytes and bone marrow MNCs
Number of subjects: 40
Study 32267881 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental and spatial determinants of enteric pathogen infection
Number of subjects: 0
Study 32267967 — intervention group
Group type: EXPERIMENTAL
Intervention: EE4A chemotherapy
Number of subjects: 0
Study 32267967 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 0
Study 32268350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation (HCT)
Number of subjects: 129
Study 32268367 — intervention group
Group type: EXPERIMENTAL
Intervention: AKCEA-APO(a)-LRx
Number of subjects: 32
Study 32268367 — intervention group
Group type: COMPARATOR
Intervention: PCSK9ab
Number of subjects: 32
Study 32268821 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (20 mg and 40 mg)
Number of subjects: 11
Study 32268821 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (60 mg)
Number of subjects: 11
Study 32268821 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (all doses)
Number of subjects: 11
Study 32268996 — intervention group
Group type: COMPARATOR
Intervention: Control participants in the Centering Pregnancy Plus Project (2008-2012)
Number of subjects: 623
Study 32269016 — intervention group
Group type: EXPERIMENTAL
Intervention: Speckle tracking echocardiography
Number of subjects: 544
Study 32269016 — intervention group
Group type: COMPARATOR
Intervention: Conventional echocardiography
Number of subjects: 544
Study 32269016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac assessment including medical history, physical examination, anthropometry, vital parameters, 1-minute sit-to-stand test, echocardiography
Number of subjects: 544
Study 32269053 — intervention group
Group type: EXPERIMENTAL
Intervention: Repotrectinib
Number of subjects: 0
Study 32269053 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study 32269051 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0084
Number of subjects: 47
Study 32269131 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART Pathway
Number of subjects: 5799
Study 32269131 — intervention group
Group type: COMPARATOR
Intervention: EDACS
Number of subjects: 5799
Study 32269142 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFN-γ) combined with high-dose cyclophosphamide (HD Cy) and low-dose interleukin (IL)-2.
Number of subjects: 2
Study 32269146 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant PROSTVAC vaccine
Number of subjects: 27
Study 32269549 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive Peripheral Nerve Sensory Stimulation and Motor Training
Number of subjects: 0
Study 32269549 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32270053 — intervention group
Group type: EXPERIMENTAL
Intervention: simeprevir 150 mg, daclatasvir 60 mg, sofosbuvir 400 mg once-daily for 12 weeks
Number of subjects: 40
Study 32270053 — intervention group
Group type: EXPERIMENTAL
Intervention: simeprevir, daclatasvir, and sofosbuvir
Number of subjects: 40
Study 32270056 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir once-daily for 12 weeks
Number of subjects: 32
Study 32270056 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert HCV VL Fingerstick assay
Number of subjects: 32
Study 32270133 — intervention group
Group type: EXPERIMENTAL
Intervention: Livelihood intervention
Number of subjects: 30
Study 32270264 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH) for 8 hours at terrestrial altitude 3840 m
Number of subjects: 16
Study 32270264 — intervention group
Group type: COMPARATOR
Intervention: Normobaric hypoxia (NH) for 8 hours
Number of subjects: 16
Study 32270313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of 327 MBq (range 299-399 MBq) of folate receptor alpha-targeted agent
Number of subjects: 6
Study 32270710 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Number of subjects: 0
Study 32271073 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Reflection and Insight Therapy (MERIT)
Number of subjects: 10
Study 32271149 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth Fit After Baby program
Number of subjects: 26
Study 32271247 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold (BRS) implantation in calcified coronary lesions
Number of subjects: 3326
Study 32271353 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg every 4 weeks) until disease progression or unacceptable toxic effects
Number of subjects: 20
Study 32271353 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 20
Study 32271464 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32271898 — intervention group
Group type: EXPERIMENTAL
Intervention: tisagenlecleucel
Number of subjects: 111
Study 32271899 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel infusion
Number of subjects: 111
Study 32271899 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel infusion with tocilizumab
Number of subjects: 111
Study 32271900 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine and rituximab (BR)
Number of subjects: 1494
Study 32271900 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine, cyclophosphamide, and rituximab (FCR)
Number of subjects: 1494
Study 32271900 — intervention group
Group type: COMPARATOR
Intervention: BR or FCR
Number of subjects: 1494
Study 32271900 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 1494
Study 32271900 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 1494
Study 32272105 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Minute Walk Test (2-MWT)
Number of subjects: 101
Study 32272183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT) with CTVp1 (60 Gy in 30 fractions)
Number of subjects: 103
Study 32272183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT) with CTVp2 (54 Gy in 30 fractions)
Number of subjects: 103
Study 32272183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT) with CTVp1 and CTVp2
Number of subjects: 103
Study 32272183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT)
Number of subjects: 103
Study 32272514 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50mg subcutaneous (SC) twice weekly for 12 weeks, followed by ETN 50mg SC once weekly for an additional 12 weeks.
Number of subjects: 80
Study 32272921 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid/long-acting β agonist (ICS/LABA)
Number of subjects: 4491
Study 32272921 — intervention group
Group type: EXPERIMENTAL
Intervention: LTRA added to ICS/LABA
Number of subjects: 4491
Study 32272921 — intervention group
Group type: COMPARATOR
Intervention: 2012 vs 2018 GINA criteria
Number of subjects: 4491
Study 32273027 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dimensional vascular ultrasound (2DVUS)
Number of subjects: 3514
Study 32273027 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional vascular ultrasound (3DVUS)
Number of subjects: 3514
Study 32273027 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score (CACS)
Number of subjects: 3514
Study 32273027 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall progression
Number of subjects: 3514
Study 32273027 — intervention group
Group type: EXPERIMENTAL
Intervention: New atherosclerosis onset
Number of subjects: 3514
Study 32273027 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with baseline disease (n=432)
Number of subjects: 3514
Study 32273098 — intervention group
Group type: EXPERIMENTAL
Intervention: Emblok embolic protection system
Number of subjects: 20
Study 32273272 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient neonatal diabetes mellitus (TNDM) participants
Number of subjects: 27
Study 32273272 — intervention group
Group type: EXPERIMENTAL
Intervention: TNDM participants
Number of subjects: 27
Study 32273272 — intervention group
Group type: COMPARATOR
Intervention: Relatives of TNDM participants
Number of subjects: 27
Study 32273476 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) 1.8 mg/kg on day 1, and DHAP (dexamethasone 40mg days 1-4, cisplatin 100mg/m2; day 1, cytarabine 2x2g/m2; day 2)
Number of subjects: 55
Study 32273476 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) combined with DHAP
Number of subjects: 55
Study 32273476 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) with DHAP
Number of subjects: 55
Study 32274381 — intervention group
Group type: EXPERIMENTAL
Intervention: YH4808 (potassium-competitive acid blocker); specific dosage and duration not mentioned.
Number of subjects: 0
Study 32274381 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin and clarithromycin; specific dosages and duration not mentioned.
Number of subjects: 0
Study 32274380 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of gemigliptin/metformin sustained release 25/500 mg
Number of subjects: 0
Study 32274380 — intervention group
Group type: COMPARATOR
Intervention: Loose combination of gemigliptin 50 mg and metformin extended release (XR) 500 mg
Number of subjects: 0
Study 32274878 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring of potassium, creatinine, and estimated plasma volume (ePV) 5 days a week using an approved home-based device (ABOTT i-STAT)
Number of subjects: 15
Study 32274878 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring of potassium, creatinine, and estimated plasma volume (ePV) 5 days a week
Number of subjects: 15
Study 32274897 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding (additional 600 kcal, 30 g protein, 72 g carbohydrate, and 21 g fat) in CTs
Number of subjects: 34
Study 32274897 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding in CTs
Number of subjects: 34
Study 32274897 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal-weight individuals)
Number of subjects: 34
Study 32275314 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine (Leu) concentrations
Number of subjects: 53
Study 32275314 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in Leu from early to late pregnancy (LeuLP-EP)
Number of subjects: 53
Study 32275314 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic clearance rate (MCR) of glucose
Number of subjects: 53
Study 32275314 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA2-IR
Number of subjects: 53
Study 32275867 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ733 (150 mg dose cohort)
Number of subjects: 40
Study 32275867 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ733 (600 mg dose cohort)
Number of subjects: 40
Study 32275867 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ733 (various doses: 75, 150, 300, 600, 900, 1200 mg)
Number of subjects: 40
Study 32275867 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ733 (600 mg dose)
Number of subjects: 40
Study 32275867 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ733
Number of subjects: 40
Study 32276015 — intervention group
Group type: EXPERIMENTAL
Intervention: PQ Bypass DETOUR System
Number of subjects: 78
Study 32277009 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medications washout
Number of subjects: 120
Study 32277401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 1147
Study 32277401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 1147
Study 32277401 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1147
Study 32277401 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 1147
Study 32277401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (both doses)
Number of subjects: 1147
Study 32277401 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride or Insulin glargine
Number of subjects: 1147
Study 32278118 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus additive enhanced diet with supplemental calcium (experimental diet) for 2 weeks
Number of subjects: 0
Study 32278118 — intervention group
Group type: COMPARATOR
Intervention: Run-in control diet for 2 weeks
Number of subjects: 0
Study 32278280 — intervention group
Group type: EXPERIMENTAL
Intervention: DEB-TACE using tightly calibrated 100-μm microspheres loaded with 50 mg of doxorubicin per millilitre
Number of subjects: 131
Study 32278280 — intervention group
Group type: EXPERIMENTAL
Intervention: DEB-TACE
Number of subjects: 131
Study 32278280 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin dose
Number of subjects: 131
Study 32278280 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-morbidities and tumour response
Number of subjects: 131
Study 32278280 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 131
Study 32278355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport specialists (moderate to vigorous physical activity)
Number of subjects: 200
Study 32278355 — intervention group
Group type: COMPARATOR
Intervention: Non-sport specialists (any activity level)
Number of subjects: 200
Study 32278355 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants diagnosed with FAI
Number of subjects: 200
Study 32278355 — intervention group
Group type: COMPARATOR
Intervention: Participants without FAI
Number of subjects: 200
Study 32278382 — intervention group
Group type: EXPERIMENTAL
Intervention: PS gene editing system using adeno-associated virus 8 (AAV8) vectors
Number of subjects: 0
Study 32278621 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (200-mg run-in dose followed by eight cycles of pembrolizumab with a taxane with or without carboplatin for 12 weeks, then doxorubicin and cyclophosphamide for an additional 12 weeks)
Number of subjects: 60
Study 32278621 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 60
Study 32279228 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 400 mg once daily (QD)
Number of subjects: 60
Study 32279360 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair resistance training (RT) with sandbags/dumbbells, twice a week for 3 months
Number of subjects: 123
Study 32279360 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 123
Study 32279621 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) quartiles
Number of subjects: 555
Study 32279704 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend catch-up sleep of more than 1 hour for children who slept ≥ 9 hours on weekdays
Number of subjects: 4699
Study 32279704 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekday sleep duration < 9 hours
Number of subjects: 4699
Study 32279704 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend catch-up sleep
Number of subjects: 4699
Study 32279704 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend catch-up sleep over 1 hour
Number of subjects: 4699
Study 32279702 — intervention group
Group type: COMPARATOR
Intervention: Primary care diagnostic agreement
Number of subjects: 229
Study 32279702 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic decisions (PAP vs conservative treatment)
Number of subjects: 229
Study 32279702 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic decisions excluding indeterminate options
Number of subjects: 229
Study 32279702 — intervention group
Group type: COMPARATOR
Intervention: Final therapeutic decisions made at sleep unit
Number of subjects: 229
Study 32280086 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver surveys every four months for two years or until the PWSD passes away, followed by assessments at eight weeks and six months post-death.
Number of subjects: 250
Study 32280086 — intervention group
Group type: EXPERIMENTAL
Intervention: Validated tools to assess PWSDs' quality of life, suffering, behaviors, functional status, resource utilization.
Number of subjects: 250
Study 32280086 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative in-depth interviews with a sub-sample of caregivers.
Number of subjects: 250
Study 32280263 — intervention group
Group type: EXPERIMENTAL
Intervention: Naldemedine 0.2 mg
Number of subjects: 2328
Study 32280263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2328
Study 32280268 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine group (M): received ultrasound-guided serratus anterior plane block with 20 mL of bupivacaine hydrochloride 0.25% plus 10 mg morphine sulfate
Number of subjects: 40
Study 32280268 — intervention group
Group type: COMPARATOR
Intervention: Control group (C): received ultrasound-guided serratus anterior plane block with 20 mL of bupivacaine hydrochloride 0.25%
Number of subjects: 40
Study 32280375 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of prebiotics and probiotics
Number of subjects: 8
Study 32280513 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital exophthalmometry measurements (24.32 ± 5.17 mm for proptosis group; 18.62 ± 3.87 mm for normal group)
Number of subjects: 32
Study 32280513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hertel exophthalmometry (HE) measurements (20.87 ± 2.53 mm for proptosis group; 17.52 ± 2.67 mm for normal group)
Number of subjects: 32
Study 32280513 — intervention group
Group type: EXPERIMENTAL
Intervention: CT measurements
Number of subjects: 32
Study 32280513 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical measurements
Number of subjects: 32
Study 32280513 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital measurements
Number of subjects: 32
Study 32280513 — intervention group
Group type: COMPARATOR
Intervention: HE vs CT correlation
Number of subjects: 32
Study 32280517 — intervention group
Group type: EXPERIMENTAL
Intervention: VHZI via anterior chamber approach
Number of subjects: 9
Study 32280517 — intervention group
Group type: COMPARATOR
Intervention: VHZI via pars plana approach
Number of subjects: 9
Study 32280529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in eyes with persistent fetal vasculature (PFV)
Number of subjects: 239
Study 32280529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in eyes with posterior capsule defect (PCD)
Number of subjects: 239
Study 32280529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in eyes with posterior lenticonus (PLC)
Number of subjects: 239
Study 32280529 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery in eyes without posterior capsule abnormalities (PCA)
Number of subjects: 239
Study 32280529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in PCA patients
Number of subjects: 239
Study 32280821 — intervention group
Group type: EXPERIMENTAL
Intervention: DIL-SIB (dominant intraprostatic lesion simultaneous in-field boosts)
Number of subjects: 6
Study 32280821 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA PET (18F-DCFPyL)
Number of subjects: 6
Study 32280821 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative DIL-SIB plans
Number of subjects: 6
Study 32281541 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT OUT! Social Issue Theater program (3 moderated psychodramatic performances by trained actors)
Number of subjects: 1594
Study 32281541 — intervention group
Group type: COMPARATOR
Intervention: Usual school day (control condition)
Number of subjects: 1594
Study 32281959 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF with atrial fibrillation (AF)
Number of subjects: 819
Study 32281959 — intervention group
Group type: COMPARATOR
Intervention: HFpEF with sinus rhythm (SR)
Number of subjects: 819
Study 32282335 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-to-moderate alcohol consumption (LMAC) in NAFLD-free participants
Number of subjects: 7079
Study 32282335 — intervention group
Group type: COMPARATOR
Intervention: Nondrinking patients with NAFLD
Number of subjects: 7079
Study 32282335 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-drinking patients with NAFLD
Number of subjects: 7079